198 filings
Page 9 of 10
6-K
IMAB
I-Mab
21 May 20
I-Mab and Genexine Announce China NMPA Clearance for Phase 2 Clinical Trial of
8:50am
6-K
IMAB
I-Mab
13 May 20
Current report (foreign)
4:01pm
20-F
2019 FY
IMAB
I-Mab
29 Apr 20
Annual report (foreign)
9:13am
6-K
IMAB
I-Mab
28 Apr 20
I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202
6:14am
6-K
IMAB
I-Mab
17 Apr 20
Current report (foreign)
4:01pm
6-K
IMAB
I-Mab
8 Apr 20
Current report (foreign)
6:29am
6-K
IMAB
I-Mab
6 Apr 20
Current report (foreign)
4:06pm
6-K
IMAB
I-Mab
2 Apr 20
Initiation of development of TJC4 in China follows an ongoing Phase 1 study in U.S. for advanced solid tumors and lymphoma
4:03pm
6-K
IMAB
I-Mab
31 Mar 20
Successfully completed initial public offering raising approximately $114.5 million in gross proceeds
7:51am
6-K
IMAB
I-Mab
30 Mar 20
I-Mab Enters into Strategic Regional Partnership with Kalbe Genexine Biologics
4:02pm
6-K
IMAB
I-Mab
27 Mar 20
I-Mab Expands GlobalOut-Licensing and Business Development Efforts
8:39am
6-K
IMAB
I-Mab
23 Mar 20
I-Mab Appoints Gigi Feng as Vice President and Global Head of Corporate Communications
6:18am
6-K
IMAB
I-Mab
13 Mar 20
I-Mab Biopharma Announces Development of TJM2 to Treat Cytokine Release
4:03pm
6-K
IMAB
I-Mab
10 Feb 20
I-Mab Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
4:03pm
424B4
IMAB
I-Mab
21 Jan 20
Prospectus supplement with pricing info
6:20am
EFFECT
IMAB
I-Mab
17 Jan 20
Notice of effectiveness
12:15am
EFFECT
IMAB
I-Mab
17 Jan 20
Notice of effectiveness
12:15am
SEC STAFF
IMAB
I-Mab
15 Jan 20
SEC staff action: Order
12:00am
CORRESP
IMAB
I-Mab
15 Jan 20
Correspondence with SEC
12:00am
CERT
IMAB
I-Mab
14 Jan 20
Certification of approval for exchange listing
10:11am